4.8 Article

Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors

期刊

CELL REPORTS
卷 21, 期 2, 页码 467-481

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2017.09.056

关键词

-

资金

  1. Beatriu de Pinos fellowship of the Generalitat de Catalunya [2010 BP-A 00430]
  2. NIH [T32 CA78207, GM105773, GM104291, CA179483, HG002668]
  3. Bridge Project
  4. Koch Institute for Integrative Cancer Research at MIT
  5. DanaFarber/Harvard Cancer Center
  6. NIH (NCI) [P30 CA196521]

向作者/读者索取更多资源

Cdk7, the CDK-activating kinase and transcription factor IIH component, is a target of inhibitors that kill cancer cells by exploiting tumor-specific transcriptional dependencies. However, whereas selective inhibition of analog-sensitive (AS) Cdk7 in colon cancer-derived cells arrests division and disrupts transcription, it does not by itself trigger apoptosis efficiently. Here, we show that p53 activation by 5-fluorouracil or nutlin-3 synergizes with a reversible Cdk7(as) inhibitor to induce cell death. Synthetic lethality was recapitulated with covalent inhibitors of wild-type Cdk7, THZ1, or the more selective YKL-1-116. The effects were allele specific; a CDK7(as) mutation conferred both sensitivity to bulky adenine analogs and resistance to covalent inhibitors. Non-transformed colon epithelial cells were resistant to these combinations, as were cancer-derived cells with p53-inactivating mutations. Apoptosis was dependent on death receptor DR5, a p53 transcriptional target whose expression was refractory to Cdk7 inhibition. Therefore, p53 activation induces transcriptional dependency to sensitize cancer cells to Cdk7 inhibition.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据